Get started
Author

Akihiro Hashimoto

Observed names: A Hashimoto, A. Hashimoto
ORCID: 0009-0009-3316-2683
Observed ORCID: 0009-0009-3316-2683
OpenAlex ID: A5102849040
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
2018 · Shinichi Hasako, Miki Terasaka, et al. · Molecular Cancer Therapeutics · 89
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2019 · Hibiki Udagawa, Shinichi Hasako, et al. · Molecular Cancer Research · 77
The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2013 · Hidenori Fujita, Kazutaka Miyadera, et al. · Molecular Cancer Therapeutics · 38
TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect
2005 · Yasuji Yamamoto, Jiro Shibata, et al. · Clinical Cancer Research · 37
PDF
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [35S]GTP-?-S functional binding assay
2000 · Heng Xu, Akihiro Hashimoto, et al. · Synapse · 26
TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span
1998 · Koji Murakami, Konstanty Wierzba, et al. · Clinical & Experimental Metastasis · 25
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals
1998 · Koji Murakami, Tomokazu Matsuura, et al. · Clinical & Experimental Metastasis · 24
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells
2016 · Hidenori Fujita, Akira Gomori, et al. · PLoS ONE · 21
PDF
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2019 · Hiroki Irie, Kimihiro Ito, et al. · Molecular Cancer Therapeutics · 15
Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59)
2000 · Jiro Shibata, Toshiyuki Toko, et al. · Cancer Chemotherapy and Pharmacology · 14
TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
2019 · Kimihiro Ito, Makoto Nishio, et al. · Molecular Cancer Therapeutics · 12
The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer.
2000 · J Shibata, K Murakami, et al. · PubMed · 9
Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells
2025 · Hiromi Muraoka, Hiromi Kazuno, et al. · Cancer Science · 7
PDF
Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
2023 · Toshihiro Shibutani, Risa Goto, et al. · Scientific Reports · 3
PDF
401 TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling
2014 · M. Kato, K. Miyadera, et al. · European Journal of Cancer · 2
Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile
2011 · Hidenori Fujita, Kazutaka Miyadera, et al. · Cancer Research · 2
Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis
2011 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Cancer Research · 2
[Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
2000 · Y Basaki, K Yonekura, et al. · PubMed · 2
Abstract 4437: Pimitespib (TAS-116), an HSP90 inhibitor, overcomes resistance to androgen receptor pathway inhibitors in prostate cancer by simultaneously targeting several key resistance mechanisms
2025 · Hiromi Muraoka, Kazuhisa Minamiguchi, et al. · Cancer Research · 1
Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
2024 · Toshihiro Shibutani, Risa Goto, et al. · Scientific Reports · 1
PDF
Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth
2018 · Hidenori Fujita, Isao Miyazaki, et al. · Cancer Research · 1
Abstract 1785: MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugs
2012 · Hidenori Fujita, Masanori Kato, et al. · Cancer Research · 1
Abstract 5863: Enhanced antitumor activity of zipalertinib and amivantamab combination in EGFR mutant NSCLC models
2026 · Kohei Hayashi, Yoshimi Aoyagi, et al. · Cancer Research
Abstract B180: TAS-115 attenuates tumor-associated macrophages and enhances sensitivity to anti-PD-1 monoclonal antibody in syngeneic mouse tumors
2018 · Tomonori Haruma, Hidenori Fujita, et al. · Molecular Cancer Therapeutics
Abstract A158: Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
2018 · Shinichi Hasako, Miki Terasaka, et al. · Molecular Cancer Therapeutics
Works count: 31
Citation count: 409
H-index: 11
I10-index: 11
Year
Topic
Type